We are now a growing commercial-stage biopharma company, focused on delivering and developing RNA-targeted therapies in the rare disease space," stated , Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "We are proud to bring the first treatment for Duchenne muscular dystrophy to patients who suffer from this devastating disorder. Concurrent with our ongoing launch activities in and around the world, we are beginning to build out our commercial infrastructure in the US in preparation for a potential launch in 2016.
http://ift.tt/1Bn2w7j
http://ift.tt/1Bn2w7j
No comments:
Post a Comment